UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group

Annals of oncology, 2016-09, Vol.27 (9), p.1746-1753

2016

Volltextzugriff (PDF)

Krebsprävention heute: von der Theorie zur praktischen Umsetzung

Der Onkologe, 2022, Vol.28 (1), p.55-61

2022

Volltextzugriff (PDF)

S3-guideline colorectal cancer version 1.0

Zeitschrift fur Gastroenterologie, 2013-08, Vol.51 (8), p.753

2013

Volltextzugriff (PDF)

Neoadjuvant rectal score as individual-level surrogate for disease-free survival in rectal cancer in the CAO/ARO/AIO-04 randomized phase III trial

Annals of oncology, 2018-07, Vol.29 (7), p.1521-1527

2018

Volltextzugriff (PDF)

Impact of age on the efficacy of oxaliplatin in the preoperative chemoradiotherapy and adjuvant chemotherapy of rectal cancer: a post hoc analysis of the CAO/ARO/AIO-04 phase III trial

Annals of oncology, 2018-08, Vol.29 (8), p.1793-1799

2018

Volltextzugriff (PDF)

Wirkung von Präventionsprojekten: eine 5-Jahres-Auswertung des Projekts „Krebsprävention im Betrieb

Forum (Heidelberg), 2022-04, Vol.37 (2), p.142-145

2022

Volltextzugriff (PDF)

Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group

Annals of oncology, 2013-06, Vol.24 (6), p.1580-1587

2013

Volltextzugriff (PDF)

S3-Leitlinie „Kolorektales Karzinom” – Aktualisierung 2008

Zeitschrift für Gastroenterologie, 2008-08, Vol.46 (8), p.799-840

2008

Volltextzugriff (PDF)

Quality of life assessment in patients with metastatic colorectal cancer receiving maintenance therapy after first-line induction treatment: a preplanned analysis of the phase III AIO KRK 0207 trial

Annals of oncology, 2016-12, Vol.27 (12), p.2203-2209

2016

Volltextzugriff (PDF)

Circulating tumor cells as a biomarker for response to therapy in multiple myeloma patients treated within the GMMG-MM5 trial

Bone marrow transplantation (Basingstoke), 2017-08, Vol.52 (8), p.1194-1198

2017

Volltextzugriff (PDF)

The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG)

Leukemia, 2009-01, Vol.23 (1), p.153-161

2009

Volltextzugriff (PDF)

Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials

British journal of cancer, 2004-03, Vol.90 (6), p.1190-1197

2004

Volltextzugriff (PDF)

First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin

Annals of oncology, 2002-04, Vol.13 (4), p.566-575

2002

Volltextzugriff (PDF)

Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancer

British journal of cancer, 2006-05, Vol.94 (9), p.1293-1299

2006

Volltextzugriff (PDF)

Age and RAS status to select patients with metastatic colorectal cancer (mCRC) for initial sequential versus combination therapy including fluoropyrimidines (FP), irinotecan (Iri) and bevacizumab (Bev): XELAVIRI- study

Annals of oncology, 2018-06, Vol.29, p.v98-v99

2018

Volltextzugriff (PDF)

Impact of sex on the efficacy and safety of panitumumab plus fluorouracil and folinic acid versus fluorouracil and folinic acid alone as maintenance therapy in RAS WT metastatic colorectal cancer (mCRC). Subgroup analysis of the PanaMa-study (AIO-KRK-0212)

ESMO open, 2023-08, Vol.8 (4), p.101568-101568, Article 101568

2023

Volltextzugriff (PDF)

5-Fluorouracil induces arterial vasocontractions

Annals of oncology, 2004-04, Vol.15 (4), p.661-664

2004

Volltextzugriff (PDF)

Prognostic factors for 60-day mortality in first-line treatment of metastatic colorectal cancer (mCRC): individual patient analysis of four randomised, controlled trials by the AIO colorectal cancer study group

Annals of oncology, 2013-12, Vol.24 (12), p.3051-3055

2013

Volltextzugriff (PDF)

Randomized Phase III Study of Gemcitabine and Vinorelbine Versus Gemcitabine, Vinorelbine, and Cisplatin in the Treatment of Advanced Non-Small-Cell Lung Cancer: From the German and Swiss Lung Cancer Study Group

Journal of clinical oncology, 2004-06, Vol.22 (12), p.2348-2356

2004

Volltextzugriff (PDF)

S3 guidelines for colorectal carcinoma: results of an evidence-based consensus conference on February 6/7, 2004 and June 8/9, 2007 (for the topics IV, VI and VII)

Zeitschrift fur Gastroenterologie, 2010-01, Vol.48 (1), p.65

2010

Volltextzugriff (PDF)

Mesalazine causes a mitotic arrest and induces caspase-dependent apoptosis in colon carcinoma cells

Carcinogenesis (New York), 2003-03, Vol.24 (3), p.443-451

2003

Volltextzugriff (PDF)

Prognostic value of microsatellite instability and p53 expression in metastatic colorectal cancer treated with oxaliplatin and fluoropyrimidine-based chemotherapy

Zeitschrift fur Gastroenterologie, 2014-12, Vol.52 (12), p.1394-1401

2014

Volltextzugriff (PDF)

Predictive and prognostic value of microsatellite instability in patients with advanced colorectal cancer treated with a fluoropyrimidine and oxaliplatin containing first-line chemotherapy. A report of the AIO Colorectal Study Group

International journal of colorectal disease, 2008-11, Vol.23 (11), p.1033-1039

2008

Volltextzugriff (PDF)

1 – 25 von 183

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(162)
Mit Volltextzugriff
(125)

Publikationsform

Sprache

Englisch
(126)
Deutsch
(65)
Japanisch
(8)
Russisch
(1)

Erscheinungsjahr

n.n

Thema

Humans
(80)
Science & Technology
(63)
Life Sciences & Biomedicine
(62)
Male
(43)
Oncology
(43)
Middle Aged
(39)
Biological And Medical Sciences
(38)
Medical Sciences
(37)
Adult
(36)
Female
(36)
Aged
(29)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(27)
Colorectal Neoplasms - Drug Therapy
(19)
Hematology
(18)
Tumors
(16)
Treatment Outcome
(15)
Colorectal Neoplasms - Pathology
(14)
Colorectal Cancer
(13)
Fluorouracil - Administration & Dosage
(12)
Neoplasm Staging
(12)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group

Krebsprävention heute: von der Theorie zur praktischen Umsetzung

S3-guideline colorectal cancer version 1.0

Neoadjuvant rectal score as individual-level surrogate for disease-free survival in rectal cancer in the CAO/ARO/AIO-04 randomized phase III trial

Impact of age on the efficacy of oxaliplatin in the preoperative chemoradiotherapy and adjuvant chemotherapy of rectal cancer: a post hoc analysis of the CAO/ARO/AIO-04 phase III trial

Wirkung von Präventionsprojekten: eine 5-Jahres-Auswertung des Projekts „Krebsprävention im Betrieb

Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group

S3-Leitlinie „Kolorektales Karzinom” – Aktualisierung 2008

Quality of life assessment in patients with metastatic colorectal cancer receiving maintenance therapy after first-line induction treatment: a preplanned analysis of the phase III AIO KRK 0207 trial

Circulating tumor cells as a biomarker for response to therapy in multiple myeloma patients treated within the GMMG-MM5 trial

The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG)

Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials

First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin

Evaluation of the inflammation-based modified Glasgow Prognostic Score (mGPS) as a prognostic and predictive biomarker in patients with metastatic colorectal cancer receiving first-line chemotherapy: a post hoc analysis of the randomized phase III XELAVIRI trial (AIO KRK0110)

Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancer

Age and RAS status to select patients with metastatic colorectal cancer (mCRC) for initial sequential versus combination therapy including fluoropyrimidines (FP), irinotecan (Iri) and bevacizumab (Bev): XELAVIRI- study

Impact of sex on the efficacy and safety of panitumumab plus fluorouracil and folinic acid versus fluorouracil and folinic acid alone as maintenance therapy in RAS WT metastatic colorectal cancer (mCRC). Subgroup analysis of the PanaMa-study (AIO-KRK-0212)

5-Fluorouracil induces arterial vasocontractions

Prognostic factors for 60-day mortality in first-line treatment of metastatic colorectal cancer (mCRC): individual patient analysis of four randomised, controlled trials by the AIO colorectal cancer study group

Randomized Phase III Study of Gemcitabine and Vinorelbine Versus Gemcitabine, Vinorelbine, and Cisplatin in the Treatment of Advanced Non-Small-Cell Lung Cancer: From the German and Swiss Lung Cancer Study Group

S3 guidelines for colorectal carcinoma: results of an evidence-based consensus conference on February 6/7, 2004 and June 8/9, 2007 (for the topics IV, VI and VII)

Mesalazine causes a mitotic arrest and induces caspase-dependent apoptosis in colon carcinoma cells

Prognostic value of microsatellite instability and p53 expression in metastatic colorectal cancer treated with oxaliplatin and fluoropyrimidine-based chemotherapy

Predictive and prognostic value of microsatellite instability in patients with advanced colorectal cancer treated with a fluoropyrimidine and oxaliplatin containing first-line chemotherapy. A report of the AIO Colorectal Study Group

Suchergebnisse filtern